The multiple faces of quercetin in neuroprotection
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
This review discusses the most recent data on the potential of quercetin to confer neuroprotection. Unfortunately, most of the in vitro studies have used quercetin aglycone, which is not detectable in the plasma or in the brain after oral intake. Moreover, quercetin metabolites and glycosides seem to be less neuroprotective and penetrate the BBB less efficiently than aglycone. Surprisingly, quercetin has beneficial effects on various in vivo models of neural disorders, particularly in cerebrovascular insults; contrasting data also do exist. This may be due to an increase of BBB permeability, described in many of these animal models, which would facilitate quercetin brain penetration. Although quercetin causes no significant toxicity in several animal studies, the risk for neurotoxicity is not negligible because of its narrow therapeutic dose-range in vitro. Notably, this risk may be even higher in the case of increased quercetin access to the brain, which may occur pathologically or artificially (e.g., by liposomal preparations). Based on the referred literature, we doubt that quercetin possesses any significant efficacy in neurodegenerative disorders. Instead, therapeutic trials should focus more on the quercetin efficacy in cerebrovascular insults rather than neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polyphenols: Food sources and bioavailability
Manach, C., Scalbert, A., Morand, C., Rémésy, C., & Jiménez, L. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.5.727 · Cited by 8,175
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
Flavonoids: antioxidants or signalling molecules?
Williams, R. J., Spencer, J. P. E., & Rice-Evans, C. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.01.001 · Cited by 2,016
Blood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions
Persidsky, Y., Ramirez, S. H., Haorah, J., & Kanmogne, G. D. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9025-3 · Cited by 922 · cited 2×
“Moreover, an increase of the BBB permeability is evident in both normal aging [100] and in AD patients [101].”
BackgroundBlood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis
Farrall, A. J., & Wardlaw, J. M. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.07.015 · Cited by 882 · cited 3×
“Moreover, an increase of the BBB permeability is evident in both normal aging [100] and in AD patients [101].”
BackgroundBlood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733
Pharmacokinetics and bioavailability of quercetin glycosides in humans
Graefe, E. U., Wittig, J., Mueller, S., Riethling, A., Uehleke, B., Drewelow, B., Pforte, H., Jacobasch, G., Derendorf, H., & Veit, M. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010366 · Cited by 649 · cited 2×
“It is now accepted that after oral administration of either quercetin aglycone or any of its glycosides, no aglycone form is detectable in human plasma [8].”
BackgroundInteraction between flavonoids and the blood–brain barrier: in vitro studies
Youdim, K. A., Dobbie, M. S., Kuhnle, G., Proteggente, A. R., Abbott, N. J., & Rice‐Evans, C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01652.x · Cited by 578
Antioxidant Therapy in Acute Central Nervous System Injury: Current State
Gilgun-Sherki, Y., Rosenbaum, Z., Melamed, E., & Offen, D. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.271 · Cited by 568 · cited 2×
“Thus, it could be speculated that only people with the BBB disruption will benefit from antioxidant supplementation [82].”
BackgroundPugh, C. R., Kumagawa, K., Fleshner, M., Watkins, L. R., Maier, S. F., & Rudy, J. W. (1998) · Brain, Behavior, and Immunity · doi:10.1006/brbi.1998.0524 · Cited by 286
Cited by
Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medicine
Yang, D., Wang, T., Long, M., & Li, P. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8825387 · Cited by 638
Neuroprotective Effects of Quercetin in Alzheimer’s Disease
Khan, H., Ullah, H., Aschner, M., Cheang, W. S., & Akkol, E. K. (2019) · Biomolecules · doi:10.3390/biom10010059 · Cited by 537
Antioxidant Therapy: Current Status and Future Prospects
Firuzi, O., Miri, R., Tavakkoli, M., & Saso, L. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711803414368 · Cited by 468
Sabogal-Guáqueta, A. M., Muñoz-Manco, J. I., Ramírez-Pineda, J. R., Lamprea-Rodriguez, M., Osorio, E., & Cardona-Gómez, G. P. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.01.027 · Cited by 447
Life or death: Neuroprotective and anticancer effects of quercetin
Dajas, F. (2012) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2012.07.005 · Cited by 374
Metadata
- Authors
- Ossola, B., Kääriäinen, T. M., & Männistö, P. T.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2009-06-21
- Volume
- 8
- Issue
- 4
- Pages
- 397-409
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W1999496773
- Cited by
- 157
- References
- 14
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The multiple faces of quercetin in neuroprotection. https://app.cochat.ai/papers/10.1517/14740330903026944
- The paper
- Ossola, B., Kääriäinen, T. M., & Männistö, P. T. (2009). The multiple faces of quercetin in neuroprotection. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740330903026944
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.